Weight changes after semaglutide in severe obesity
Part of Hormones & metabolism clinical trials.
This study looks at how weight changes over time in people with severe or complicated obesity who have already started taking the medication semaglutide (brand name Wegovy). It aims to find factors that predict who will lose the most weight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are taking or have taken the weight-loss medicine semaglutide (Wegovy) through an early access program.
- You have a type of obesity called grade 3 (also known as severe or morbid obesity) or obesity with other health problems.
- You must have received at least two prescriptions or refills of Wegovy.
- You are willing to allow the researchers to use your medical records for this study.
- You are able to fill out an online questionnaire.
- You are not a minor or under legal guardianship or conservatorship.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a small implant placed under the skin that releases a weight management medicine (semaglutide) slowly over time. The goal is to see how safe it is and how your body handles it.
This trial tests a new way to deliver semaglutide through a strip placed on the tongue for weight loss in adults with obesity. It may help you lose weight without a needle.
This study tests whether slowly reducing the dose of the weight-loss medication semaglutide can help keep weight off after losing at least 10% of body weight. It compares two ways of tapering the dose to see which works better for maintaining weight loss.
This study tests a weekly injection called semaglutide to see how well it helps people with obesity lose weight, compared to a similar approved medicine, Wegovy. It may be an option if you have struggled to lose weight in the past.
This study looks at what happens to your body and weight when you stop taking semaglutide (Wegovy/Ozempic) after losing at least 10% of your starting weight. The goal is to understand how your metabolism and heart health change once the medication is paused.
This study observes how Wegovy works in everyday medical practice for people who are starting it for the first time. It will help doctors learn more about its real-life benefits and safety.
Hear when a new Obesity & Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.